You’ve probably noticed that we like to revisit subjects, no matter how exhaustive our prior analysis may have appeared. We do this for two reasons – to foster a running dialogue on a constantly evolving idea; and to make sure the Primal Blueprint remains supported by hard science.
Mark has always talked about his affection for the beach sprint (or any type of sprint) as a quick, intense, effective cardio workout in line with the type of daily activities Grok performed. He’s also conveyed his unease with our increasing reliance on Big Pharma for our health and wellness needs. Today’s post deals with two recent studies of particular interest and relevance to these topics. We found them quite interesting, and we think our readers might too.
Last month we brought you news (and humble perspective) on the pharmaceutical industry’s off-label marketing practices. Just a couple weeks after the fact, what before our wondering eyes should appear? News that a glaucoma drug (Lumigan) was just approved by the FDA for off-label use as an eyelash enhancer. Call us suckers, we know, but we couldn’t resist taking the bite. Finding new uses for existing poor selling drugs has become a cottage industry. Reminds me of the old SNL skit, “Shimmer. It’s a dessert topping AND a floor wax!”
I’ve been a faithful reader of your blog for a couple of months now since Tony Horton turned me on to it at one of his fitness camps. Anyway, the reason I am writing today is to refer you to an article about some scientists who are proposing “cognitive enhancing drugs” for healthy people. I had to check the dateline to make sure it wasn’t recycled from April 1st. I’m sure you’ll be interested in it and I’m sure your readers would enjoy your commentary on it:
Thanks to reader Dave for forwarding the article. A number of people I know actually sent me the news with various questions and comments of their own. It’s made for a lot of interesting conversations, shall we say, in the last several days.
What can we say? We’ve got Pharma on the mind this week! On Monday Mark offered commentary on the latest “study” being spun to further promote statins to the general population. It seemed like an opportune time to bring you news of a recent report on the “unofficial” business of off-label pharmaceutical marketing and the clever manipulation of drug approval rules and research dissemination.
Two researchers with significant experience in the pharmaceutical industry, Adriane Fugh-Berman, M.D., an associate professor in the GUMC Department of Physiology and Biophysics, and Douglas Melnick, M.D., a preventive medicine physician in the Los Angeles County Department of Public Health have published a report in the free online journal PLoS Medicine shedding light on risky and legally questionable practices that have become commonplace in the industry.
“A New Front on Heart Disease: Stain drugs can cut cardiac and stroke risks in people with normal cholesterol levels, researchers say.” Wow! As I predict Dr. Michael Eades will say, “Jesus wept.” As I say, “here we go again digging a hole to place the ladder in so you can wash the basement windows.”
© 2013 Mark's Daily Apple | Design By The Blog Studio